BAJAJ BROKING

Notification
No new Notification messages
Retaggio Industries IPO is Open!
Apply for the Retaggio Industries IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Senores Pharmaceuticals Ltd

Pharmaceuticals

Offer Period :

20th to 24th Dec 2024

Senores Pharmaceuticals Ltd IPO Details

IPO Date 20th to 24th Dec 2024 Minimum Investment ₹14858 / 1 Lots
Listing Date 2024-12-30 Maximum Investment ₹193154 / 13 Lots
Face Value ₹10 per share Total Issue Size ₹582.11 Crores
Price ₹391 to ₹391 per share Fresh Issue ₹500 Crores
Lot Size 1 Lots (38 Shares) Offer For Sale ₹ [-]
Listing At BSE, NSE Retail Discount ₹ 0
Employee Discount ₹0 per Share Shareholding Pre Issue 33265865 Shares
Issue Type Book Building Shareholding Post Issue 46053589 Shares
IPO Date 20th to 24th Dec 2024
Listing Date 2024-12-30
Face Value ₹10 per share
Price ₹391 to ₹391 per share
Lot Size 1 Lots (38 Shares)
Listing At BSE, NSE
Total Issue Size ₹582.11 Crores
Employee Discount ₹0 per share
Issue Type Book Building
Minimum Investment ₹14858 / 1 Lots
Maximum Investment ₹193154 / 13 Lots
Fresh Issue ₹500 Crores
Offer For Sale ₹[-] Crores
Retail Discount ₹0 Crores
Shareholding Pre Issue 33265865 Shares
Shareholding Post Issue 46053589 Shares

About Senores Pharmaceuticals Ltd IPO

Founding Head: 2017

Managing Director: Swapnil Jatinbhai Shah

SENORES PHARMACEUTICALS LIMITED Timeline

Important dates for allocation and IPO listing.

20th Dec

IPO Opens

24th Dec

IPO Close

26th Dec

Allotment Date

26th Dec

Initiation of Refund

27th Dec

Credit of Shares to Demat Account

-

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 66.66 45.76
Public Group 33.34 54.24

Senores Pharmaceuticals Ltd IPO Reservation

QIB Shares Offered 4443817(29.85%)
NII (HNI) Shares Offered 2221909(14.92%)
Retail Shares Offered 1481272(9.95%)
Anchor Investor Shares Offered 6665726(44.77%)
Total Shares Offered 14887724
Total Shares With Anchor Investor 14887724

Senores Pharmaceuticals Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 38 ₹14858
Retail (Max) 13 494 ₹193154
S HNI (Min) 14 532 ₹208012
S HNI (Max) 67 2546 ₹995486
B HNI (MIN) 68 2584 ₹1010344

Senores Pharmaceuticals Ltd IPO Anchor Investor Details

Bid Date 19 December 2024
Shares Offered 0
Anchor Portion Size 0

Senores Pharmaceuticals Ltd IPO Registrar

MUFG Intime India Pvt Ltd
Phone Number +91 8108114949
Email Id senorespharma.ipo@linkintime.co.in
Our Website www.linkintime.co.in

Senores Pharmaceuticals Ltd IPO Lead Manager

1. Equirus Capital Pvt Ltd

2. Ambit Pvt Ltd

3. Nuvama Wealth Management Ltd

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Senores Pharmaceuticals Ltd Financial Information

Period Ended March 31, 2024 March 31, 2023 March 31, 2022
Net Worth ₹168.12 ₹38.19 ₹33.69
Reserves and Surplus ₹137.61 ₹28.38 ₹24.95
Total Borrowing ₹92.76 ₹59 ₹14.21

Senores Pharmaceuticals Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 4593216 434778102 94.66
Non Institutional Investors (NIIs) 2319879 222963632 96.11
NII(Bid amount of more than Ten Lakh Rupees) 1546586 144653764 93.53
NII(Bid amount of more than 2 Lakh < 10 Rupees) 773293 78309868 101.27
Retail Individual Investors (RIIs) 1546586 137996278 89.23
Total 8534681 797232134 93.41

Strength of Senores Pharmaceuticals Ltd

1. Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.

2. Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.

3. Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.

4. Presence in the Emerging Markets with a product portfolio, including specialty or complex products.

5. R&D capabilities driving our differentiated portfolio of products.

6. Professional management teams for our diverse business verticals.

Risks Involved

1. The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.

2. The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.

3. Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.

4. The company derives a part of its revenue from few customers. If one or more of such customers choose not to source their requirements from it or to terminate the company contracts or purchase orders, its business, cash flows, financial condition and results of operations may be adversely affected.

5. The company has had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on its business and operations.

6. The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations. There have been instances in the past where the company drugs failed to meet standards prescribed under applicable law and action was taken against it by regulatory authorities.

7. The company derives a major portion of its revenue from its operations in the United States. A reduction in demand for the company products in these regions could adversely affect its business, results of operations, financial conditions and cash flows.

8. Any manufacturing or quality control problems may damage its reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, results of operations and financial condition.

9. Some of its Directors and Promoters may have interest in entities, which are in businesses similar to its and this may result in conflict of interest with it. Further, certain of its Promoter Group, Subsidiaries and Group Companies are in the same line of business as it, which may result in a conflict of interest.

10. The erstwhile statutory auditors of the Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.

Why should you invest in

-

Senores Pharmaceuticals Ltd Financials

Particulars For the financial year ending (in ₹ million)
  2024 2023 2022
Total Assets 621.88 131.05 59.15
Total Liabilities 621.88 131.05 59.15
Total Expenses 192.4 26.58 13.49
Total Revenue 
217.34 39.02 14.63
Profit After Tax 31.45 8.43 0.99
EBITDA 44.41 16.35 2.41
Adjusted EBITDA 0 0 0

SENORES PHARMACEUTICALS LIMITED IPO Contact Details

Senores Pharmaceuticals Ltd IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
2024-12-30 544319 SENORES
INE0RB801010
₹391 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹391 ₹391
Open ₹593.7 ₹600
Low ₹538.85 ₹538.85
High ₹609 ₹609.65
Low ₹538.85 ₹538.85

Frequently Asked Questions

What is Senores Pharmaceuticals Ltd IPO?

Answer Field

Senores Pharmaceuticals Ltd IPO is a Mainboard IPO of 1,48,87,724 equity shares of a face value of ₹10 aggregating up to ₹582.11 Crores. The issue is priced at ₹391 to ₹391 per share. The minimum order quantity is 38 Shares. The IPO opens on December 20, 2024, and closes on December 24, 2024. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Senores Pharmaceuticals Ltd IPO will open?

Answer Field

The Senores Pharmaceuticals Ltd IPO opens on December 20, 2024 and closes on December 24, 2024.

What is the lot size of Senores Pharmaceuticals Ltd?

Answer Field

Senores Pharmaceuticals Ltd lot size is 38 shares, and the minimum amount required is ₹14,858.

How to apply for Senores Pharmaceuticals Ltd IPO?

Answer Field

You can apply in Senores Pharmaceuticals Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Senores Pharmaceuticals Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Senores Pharmaceuticals Ltd IPO will be done on December 26, 2024, and the allotted shares will be credited to your demat account by December 27, 2024.

When is Senores Pharmaceuticals Ltd IPO listing date?

Answer Field

The Senores Pharmaceuticals Ltd listing date is December 30, 2024.

Who is the registrar of Senores Pharmaceuticals Ltd IPO?

Answer Field

The registrar of Senores Pharmaceuticals Ltd IPO is MUFG Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Equirus Capital Pvt Ltd,Ambit Pvt Ltd,Nuvama Wealth Management Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Senores Pharmaceuticals Ltd IPO?

Answer Field

The fresh issue size is ₹500 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Senores Pharmaceuticals Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 38 shares and ₹14,858 amount.

How can I approve the UPI mandate request for Senores Pharmaceuticals Ltd IPO?

Answer Field

To apply for Senores Pharmaceuticals Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Senores Pharmaceuticals Ltd?

Answer Field

The price of each Senores Pharmaceuticals Ltd share will be ranging in between ₹391 to ₹391 per share.

What is the cut-off time for the UPI mandate for Senores Pharmaceuticals Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 24, 2024.

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • VOLER CAR LIMITEDSME IPO

  • Issue Price

    90.00

  • Listing Day Close

    91.45

  • Listing Day (Gain/Loss)

    1.11

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9 lakh+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text